Le Bruyère 2000 - Bat 2
Zone le Millénaire, 650 rue Henri Becquerel
Tel: 33 4 67 20 77 30
151 articles about Sensorion
SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of SENS-111 on vertigo intensity
Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management
Sensorion announced a €4.7 million nominal bond issue, consisting of one (i) convertible bond issue1 for a nominal amount of €3,4 million subscribed by several new European investors as well as a bond issue2 for a nominal amount of €1.3 million subscribed by these same European investors for an amount of €1 million and the balance by the Company's management, Mr. Patrick Langlois, Chairman of the Board of Directors and Ms. Nawal Ouzren, Chief Executive Officer.
Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant...
12/19/2017The collaboration will evaluate therapeutic approaches using SENS-401 in combination with cochlear implants, with preclinical studies initiating in 2018, and potential clinical trials to begin as soon as 2019.
Sensorion announces its results for the first half of the year ending June 30, 2017, as well as its recent developments.
Sensorion Strengthens Its Financial Structure With The Exercise Of The Second Tranche Of Its Financing Agreement
Sensorion, The Specialist In Inner Ear Diseases, Completes A New Funding Round To Begin The Human Clinical Trial Phase